YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. On Wednesday, Curis Inc. announced updated positive clinical trial results for its investigational drug emavusertib, alongside expanded tr…
Curis has opened enrolment at 11 clinical sites for its Phase II TakeAim CLL trial to assess the oral small molecule inhibitor emavusertib, along with zanubrutinib, for patients with chronic lymphocytic leukaemia (CLL). The company also re…
Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest update on Curis keeps the fair value price target steady at US$14.00, even as other as…
Vericel Corporation (VCEL) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items.…
Kiniksa Pharmaceuticals International, plc (KNSA) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.11 per share a year ago. These figures are adju…
Curis, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Pivot to Combination Therapy and Disease Modification Management is transitioning from monotherapy to a dual-blockade strategy, combining emavusertib with BTK inhibitors to target…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Curis is back in focus as analysts reaffirm a $14.00 per share fair…
(RTTNews) - U.S. after-hours trading on Wednesday saw a wave of gains across several small-cap and micro-cap biotech names, with a mix of catalyst-driven moves and sentiment-based rebounds. While a few companies advanced on upcoming clinic…
Curis (CRIS) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to a loss of $1.7 per share a year ago. These figures are adjusted for non-recurring items. This quarterly…
Major earnings expected before the bell on Tuesday include: * Pfizer (PFE [https://seekingalpha.com/symbol/PFE]) * Caterpillar (CAT [https://seekingalpha.com/symbol/CAT]) * BP p.l.c. (BP [https://seekingalpha.com/symbol/BP]) * Organon & Co…
* Curis (NASDAQ:CRIS [https://seekingalpha.com/symbol/CRIS]) has entered into a definitive agreement for the purchase of 1.5M shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. * In a concur…
LEXINGTON, Mass. - Biotechnology company Curis, Inc. (NASDAQ:CRIS), currently valued at $22.49 million and showing weak financial health according to InvestingPro metrics, announced Wednesday it has secured approximately $7 million in fina…
The market expects Insmed (INSM) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2025. This widely-known consensus outlook is important in assessing the company's earni…
LEXINGTON, Mass., Jan. 5, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 2, 2024, the independent…
Curis, Inc. (NASDAQ:CRIS) shareholders would be excited to see that the share price has had a great month, posting a 54% gain and recovering from prior weakness. Taking a wider view, although not as strong as the last month, the full year…
LEXINGTON, Mass., Dec. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced initial combinati…
LEXINGTON, Mass., Dec. 11, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, last night presented clinical dat…
LEXINGTON, Mass., Dec. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company a…
LEXINGTON, Mass., Dec. 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entere…
Curis, Inc. (NASDAQ:CRIS) Q3 2023 Earnings Call Transcript November 2, 2023 Curis, Inc. beats earnings expectations. Reported EPS is $-2.13, expectations were $-2.32. Operator: Good morning, and welcome to Curis' Third Quarter 2023 Busines…
Curis Inc (NASDAQ:CRIS) reported a net loss of $12.2 million for Q3 2023, a decrease compared to $13.3 million for the same period in 2022. Revenues for Q3 2023 remained steady at $2.8 million, the same as Q3 2022. The company maintains a…
Continued progress on the development of emavusertib Strong balance sheet with $68.5 million in cash and investments; cash runway into 2025 Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., Nov. 2, 2023 /PRNewswire…
2seventy bio, Inc. (TSVT) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2023. This widely-known consensus outlook gives a good sense of the company's…
LEXINGTON, Mass., Oct. 26, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancie…
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune…
LEXINGTON, Mass., Oct. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on October 2, 2023, the independent…
Pharming Group N.V. Sponsored ADR (PHAR) shares rallied 14.7% in the last trading session to close at $15.98. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compa…
Symposium hosted by Guillermo Garcia-Manero, M.D. and Eric Winer, M.D. Academics and industry professionals will gather virtually on September 22, 2023 LEXINGTON, Mass., Sept. 12, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechn…
LEXINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment of hematologic malignancies…
Curis, Inc. (NASDAQ:CRIS) Q2 2023 Earnings Call Transcript August 3, 2023 Curis, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $0.12. Operator: Good afternoon and welcome to the Curis’ Second Quarter 2…
Curis (CRIS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expect…
Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance sheet with $77.4 million in cash and invest…
LEXINGTON, Mass., July 27, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor for the treatment of hematologic malignancie…
LEXINGTON, Mass., July 6, 2023 /PRNewswire/ -- Curis, Inc., (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, an orally available small molecule triple target inhibitor (IRAK4, FLT3 and CLK) for the treatme…
LEXINGTON, Mass., July 6, 2023 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib, a triple target inhibitor (IRAK4, FLT3 and CLK) for the treatment of hematologic malignancies, to…
It is doubtless a positive to see that the Curis, Inc. (NASDAQ:CRIS) share price has gained some 39% in the last three months. But that can't change the reality that over the longer term (five years), the returns have been really quite dis…